Overview
CPRX market data
Price History
CPRX price chart
Valuation & Profitability
- P/E (TTM)
- 17.42 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.68 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.30 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 37.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $19.05 – $32.56 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.9B · P/B 3.01 · P/S 6.46.
Company News
Angelini Pharma Completes Acquisition of Catalyst PharmaceuticalsGlobenewswire Inc · Jul 16, 2026, 11:00 AM
8-K filing — CATALYST PHARMACEUTICALS, INC. (CPRX)SEC EDGAR · Jul 15, 2026, 9:36 PM
Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026Benzinga · Jul 9, 2026, 9:25 PM
Catalyst Pharmaceuticals Announces Topline Results From Two-Part Phase 1 Clinical Study Of Vamorolone In Healthy Adult VolunteersBenzinga · Jun 30, 2026, 12:15 PM
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals to Neutral, Lowers Price Target to $31.5Benzinga · May 28, 2026, 4:43 PM